New Publication from IMPACT Trial: Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy
The IMPACT trial – a double blind randomized placebo controlled study – was designed to test whether young, peanut allergic children (12-48 months) could be desensitized with peanut oral immunotherapy (OIT) and ultimately remain non-responsive to peanut after discontinuation of OIT.
New Publication from EXTEND Trial: IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes
The EXTEND trial was a double blind randomized placebo controlled study designed to test the effect of IL-6 receptor blockade (tocilizumab) in pediatric participants (age 6-17 years) with new onset type 1 diabetes. IL-6 pathway blockade is an effective immunotherapy in some autoimmune diseases including juvenile idiopathic arthritis and rheumatoid arthritis working, at
The Immune Tolerance Network (ITN) is a collaborative network for clinical research, funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The ITN, headquartered at the Benaroya Research Institute (BRI) in Seattle WA, has major operations centers at BRI and in San Francisco at University of California San Francisco (UCSF).
This is a UCSF position
Christian P. Larsen, MD, DPhil, the Immune Tolerance Network’s (ITN’s) deputy director in transplantation, transplant surgeon, and immunologist was presented with the 2021 American Medical Association (AMA) Scientific Achievement Award.
New Publication: Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis
The PAUSE trial was conducted to determine whether blocking CD28/B7 costimulatory signaling with abatacept would prevent relapse of psoriasis after effective treatment with ustekinumab (an IL12/23 antagonist).
In an article published today in Frontiers in Immunology, Immune Tolerance Network (ITN) leadership and clinical trial physicians review ITN's approach to the development of therapies that aim to establish tolerance in immune mediated diseases.
The ITN article that reported the results of the CATEEC clinical trial, which compared clinical and biological responses to cat allergen exposure by nasal allergen challenge (NAC) or environmental exposure chamber (EEC) was selected to be an Editors’ Choice feature and was displayed on the American Academy of Allergy Asthma & Immunology (AAAAI) website.
The first patient first visit (FPFV) has occurred for ITN’s REBOOT clinical trial. REBOOT is a clinical study that aims to evaluate the safety and effectiveness of belimumab and intravenous rituximab at inducing remission of primary membranous nephropathy (MN) compared to rituximab alone.